Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection

Antiviral Research

Volumn 64, Issue 1, 2004, Pages 1-15

  Zoulim, Fabien ^a  

^a INSERM   (France)

Author keywords

Hepatitis B, Viral persistence, Viral resistance, Viral clearance, Nucleosides, Nucleotides, Immunopathology

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; CYTIDINE DERIVATIVE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; GAMMA INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PENCICLOVIR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TELBIVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; ENZYME ACTIVITY; HEPATITIS B VIRUS; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PERSISTENT VIRUS INFECTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; NUCLEOTIDES; PHENOTYPE; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 4744354693     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2004.07.003     Document Type: Review

References (143)

1. M.I. Allen, M. Deslauriers, C.W. Andrews, G.A. Tipples, K.A. Walters, D.L.J. Tyrell, N. Brown, and L.D. Condreay Identification and characterization of mutations in hepatitis B virus resistant to Lamivudine Hepatology 27 1998 1670 1677
2. P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology 125 2 2003 292 297
3. M.I. Barrasa, J.T. Guo, J. Saputelli, W.S. Mason, and C. Seeger Does a cdc2 kinase-like recognition motif on the core protein of hepadnaviruses regulate assembly and disintegration of capsids J. Virol. 75 4 2001 2024 2028
4. A. Bartholomeusz, and S. Locarnini Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine Int. Antivir. News 5 1997 123 124
5. A. Bartholomeusz, B.G. Tehan, and D.K. Chalmers Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations Antivir. Ther. 9 2 2004 149 160
6. A. Bertoletti, and N.V. Naoumov Translation of immunological knowledge into better treatments of chronic hepatitis B J. Hepatol. 39 1 2003 115 124
7. T.M. Block, and R. Jordan Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs Antivir. Chem. Chemother. 12 6 2001 317 325
8. T.M. Block, X. Lu, A.S. Mehta, B.S. Blumberg, B. Tennant, M. Ebling, B. Korba, D.M. Lansky, G.S. Jacob, and R.A. Dwek Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking Nat. Med. 4 5 1998 610 614
9. C. Boni, A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scognamiglio, R. Boehme, R. Panebianco, F. Fiaccadori, and C. Ferrari Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B [see comments] J. Clin. Invest. 102 5 1998 968 975
10. C. Boni, A. Penna, G.S. Ogg, A. Bertoletti, M. Pilli, C. Cavallo, A. Cavalli, S. Urbani, R. Boehme, R. Panebianco, F. Fiaccadori, and C. Ferrari Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy Hepatology 33 4 2001 963 971
11. B. Böttcher, N. Tsuji, H. Takahashi, M. Dyson, S. Zhao, R.A. Crowther, and K. Murray Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection EMBO J. 17 1998 6839 6845
12. E. Bridges, and Y. Cheng Use of novel b-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma Progress in Liver Diseases 1995
13. V.J. Cavanaugh, L. Guidotti, and F.V. Chisari Interleukine-12 inhibits hepatitis B virus replication in transgenic mice J. Virol. 71 1997 3236 3243
14. M.-H. Chang, C.-J. Chen, M.-S. Lai, H.-M. Hsu, T.-C. Wu, M.-S. Kong, D.-C. Liang, W.-Y. Shau, and D.-S. Chen Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children N. Engl. J. Med. 336 1997 1855 1859
15. F. Chisari Hepatitis B virus transgenic mice: insights into the virus and the disease Hepatology 22 1995 1316 1325
16. J. Colacino Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU) Antivir. Res. 29 1996 125 139
17. D. Colledge, G. Civitico, S. Locarnini, and T. Shaw In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir [in process citation] Antimicrob. Agents Chemother. 44 3 2000 551 560
18. D. Colledge, S. Locarnini, and T. Shaw Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro Hepatology 26 1997 216 225
19. L. Condreay, J. Condreay, R. Jansen, M. Paff, and D. Averett (-)-Cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes Antimicrob. Agents Chemother. 40 1996 520 523
20. L. Condreay, R. Jansen, T. Powdrill, L. Johnson, D. Selleseth, M. Paff, S. Daluge, G. Painter, P. Furman, M. Ellis, and D. Averett Evaluation of the potent anti-HBV agent (-)cis-5-fluoro-1(2-(hydroxymethyl)-1,3-oxathiolan-5-yl) cytosine in a novel in vivo model Antimicrob. Agents Chemother. 38 1994 616 619
21. K. Das, X. Xiong, H. Yang, C.E. Westland, C.S. Gibbs, S.G. Sarafianos, and E. Arnold Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) J. Virol. 75 10 2001 4771 4779
22. E. De Clercq Perspectives for the treatment of hepatitis B virus infections Int. J. Antimicrob. Agents 12 2 1999 81 95
23. E. De Clercq Antiviral drugs: current state of the art J. Clin. Virol. 22 1 2001 73 89
24. W.E. Delaney, and H.C. Isom Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus Hepatology 28 1998 1134 1146
25. W.E.t. Delaney, R. Edwards, D. Colledge, T. Shaw, P. Furman, G. Painter, and S. Locarnini Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro Antimicrob. Agents Chemother. 46 9 2002 3057 3060
26. W.E.t. Delaney, R. Edwards, D. Colledge, T. Shaw, J. Torresi, T.G. Miller, H.C. Isom, C.T. Bock, M.P. Manns, C. Trautwein, and S. Locarnini Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus Antimicrob. Agents Chemother. 45 6 2001 1705 1713
27. W.E.t Delaney, H. Yang, C.E. Westland, K. Das, E. Arnold, C.S. Gibbs, M.D. Miller, and S. Xiong The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro J. Virol. 77 21 2003 11833 11841
28. J. Delmas, O. Schorr, C. Jamard, C. Gibbs, C. Trepo, O. Hantz, and F. Zoulim Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro Antimicrob. Agents Chemother. 46 2 2002 425 433
29. K. Deres, C.H. Schroder, A. Paessens, S. Goldmann, H.J. Hacker, O. Weber, T. Kramer, U. Niewohner, U. Pleiss, J. Stoltefuss, E. Graef, D. Koletzki, R.N. Masantschek, A. Reimann, R. Jaeger, R. Gross, B. Beckermann, K.H. Schlemmer, D. Haebich, and H. Rubsamen-Waigmann Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids Science 299 5608 2003 893 896
30. Durantel, D., Carrouée-Durantel, S., Werle-Lapostolle, B., Brunelle, M.N., Pichoud, C., Trépo, C., Zoulim, F., in press. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology.
31. D. Fallows, and S. Goff Mutations in the e sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription J. Virol. 69 1995 3067 3073
32. G. Fourel, C. Trepo, L. Bougueleret, B. Henglein, A. Ponzetto, P. Tiollais, and M.A. Buendia Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumors Nature 347 1990 294 298
33. I. Fourel, J. Saputelli, P. Schaffer, and W.S. Mason The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver J. Virol. 68 1994 1059 1065
34. L. Fu, and Y.-C. Cheng Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance Biochem. Pharmacol. 55 1998 1567 1572
35. L. Fu, and Y.-C. Cheng Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus [in process citation] Antimicrob. Agents Chemother. 44 12 2000 3402 3407
36. L. Fu, S.H. Liu, and Y.-C. Cheng Sensitivity of L-(-)2,3- dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues Biochem. Pharmacol. 57 12 1999 1351 1359
37. D. Ganem, and A.M. Prince Hepatitis B virus infection - natural history and clinical consequences N. Engl. J. Med. 350 11 2004 1118 1129
38. J. Gauthier, E.J. Bourne, M.W. Lutz, L.M. Crowther, J.L. Dienstag, N.A. Brown, and L.D. Condreay Quantitation of Hepatitis B viremia and emergence of YMDD variants in patients with chronic Hepatitis B treated with lamivudine J. Infect. Dis. 180 6 1999 1757 1762
39. R.G. Gish, N.W. Leung, T.L. Wright, H. Trinh, W. Lang, H.A. Kessler, L. Fang, L.H. Wang, J. Delehanty, A. Rigney, E. Mondou, A. Snow, and F. Rousseau Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection Antimicrob. Agents Chemother. 46 6 2002 1734 1740
40. P. Gripon, S. Rumin, S. Urban, J. Le Seyec, D. Glaise, I. Cannie, C. Guyomard, J. Lucas, C. Trepo, and C. Guguen-Guillouzo Infection of a human hepatoma cell line by hepatitis B virus Proc. Natl. Acad. Sci. U.S.A. 99 24 2002 15655 15660
41. L.G. Guidotti, P. Borrow, A. Brown, H. McClary, R. Koch, and F.V. Chisari Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte J. Exp. Med. 189 10 1999 1555 1564
42. L.G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F.V. Chisari Viral clearance without destruction of infected cells during acute HBV infection Science 284 5415 1999 825 829
43. S. Günther, L. Fischer, I. Pult, M. Sterneck, and H. Will Naturally occuring variants of hepatitis B virus Adv. Virus Res. 52 1999 25 137
44. S. Günther, B.-C. Li, S. Miska, D. Kruger, H. Meisel, and H. Will A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients J. Virol. 69 1995 5437 5444
45. J.T. Guo, H. Zhou, C. Liu, C. Aldrich, J. Saputelli, T. Whitaker, M.I. Barrasa, W.S. Mason, and C. Seeger Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections [in process citation] J. Virol. 74 3 2000 1495 1505
46. J.H. Hoofnagle, and A.M. Di Bisceglie The treatment of chronic viral hepatitis N. Engl. J. Med. 336 1997 347 356
47. J. Hu, D. Toft, and C. Seeger Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids EMBO J. 16 1997 59 68
48. J.R. Jacob, A. Sterczer, I.A. Toshkov, A.E. Yeager, B.E. Korba, P.J. Cote, M.A. Buendia, J.L. Gerin, and B.C. Tennant Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors Hepatology 39 4 2004 1008 1016
49. A.C. Jacquard, M. Nassal, C. Pichoud, S. Ren, U. Schultz, S. Guerret, M. Chevallier, B. Werle, S. Peyrol, C. Jamard, L.T. Rimsky, C. Trepo, and F. Zoulim Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection Antimicrob. Agents Chemother. 48 7 2004 2683 2692
50. K. Kajino, A. Jilbert, J. Saputelli, C. Aldrich, J. Cullen, and W. Mason Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte J. Virol. 68 1994 5792 5803
51. J.H. Kao, N.H. Wu, P.J. Chen, M.Y. Lai, and D.S. Chen Hepatitis B genotypes and the response to interferon therapy J. Hepatol. 33 6 2000 998 1002
52. R.W. King, S.K. Ladner, T.J. Miller, K. Zaifert, R.B. Perni, S.C. Conway, and M.J. Otto Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)b-L-2′, 3′-dideoxy-3′-thiacytidine Antimicrob. Agents Chemother. 42 1998 3179 3186
53. C. Klein, C.T. Bock, H. Wedemeyer, T. Wustefeld, S. Locarnini, H.P. Dienes, S. Kubicka, M.P. Manns, and C. Trautwein Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA Gastroenterology 125 1 2003 9 18
54. J. Kock, T.F. Baumert, W.E.t. Delaney, H.E. Blum, H.E. Blum, and F. von Weizsacker Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes Hepatology 38 6 2003 1410 1418
55. B.E. Korba In vitro evaluation of combination therapies against hepatitis B virus replication Antivir. Res. 29 1 1996 49 51
56. B.E. Korba, P. Cote, W. Hornbuckle, R. Schinazi, J.L. Gerin, and B.C. Tennant Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks Antivir. Res. 45 1 2000 19 32
57. S. Ladner, T.J. Miller, and R.W. King The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′- thiacytidine and a reduced ability to synthesize viral DNA Antimicrob. Agents Chemother. 42 1998 2128 2131
58. S.K. Ladner, M.J. Otto, C.S. Barker, K. Zaifert, G.-H. Wang, J.-T. Guo, C. Seeger, and R.W. King Inducible expression of human hepatitis B virus (HBV) instably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication Antimicrob. Agents Chemother. 41 1997 1715 1720
59. C.L. Lai, J. Dienstag, E. Schiff, N.W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin. Infect. Dis. 36 6 2003 687 696
60. R. Lanford, L. Notvall, and B. Beames Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells J. Virol. 69 1995 4431 4439
61. R.E. Lanford, D. Chavez, K.M. Brasky, R.B. Burns, and R. Ricco-Hesse Isolation of a hepadnavirus from the woolly monkey, a new world primate Proc. Natl. Acad. Sci. U.S.A. 95 1998 5757 5761
62. R.E. Lanford, D. Chavez, R. Rico-Hesse, and A. Mootnick Hepadnavirus infection in captive gibbons J. Virol. 74 6 2000 2955 2959
63. G.K. Lau, M. Tsiang, J. Hou, S. Yuen, W.F. Carman, L. Zhang, C.S. Gibbs, and S. Lam Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study [see comments] Hepatology 32 2 2000 394 399
64. F. Le Guerhier, C. Pichoud, S. Guerret, M. Chevallier, C. Jamard, O. Hantz, X.Y. Li, S.H. Chen, I. King, C. Trepo, Y.-C. Cheng, and F. Zoulim Characterization of the antiviral effect of 2′,3′-dideoxy-2′, 3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model Antimicrob. Agents Chemother. 44 1 2000 111 122
65. F. Le Guerhier, A. Thermet, S. Guerret, M. Chevallier, C. Jamard, C.S. Gibbs, C. Trepo, L. Cova, and F. Zoulim Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model J. Hepatol. 38 3 2003 328 334
66. K. Lee, and C.K. Chu Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents Antimicrob. Agents Chemother. 45 1 2001 138 144
67. W.M. Lee Hepatitis B virus infection N. Engl. J. Med. 337 1997 1733 1745
68. R. Lenhoff, and J. Summers Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes J. Virol. 68 1994 5706 5713
69. R. Lenhoff, and J. Summers Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus J. Virol. 68 1994 4565 4571
70. S. Levine, D. Hernandez, G. Yamanaka, S. Zhang, R. Rose, S. Weinheimer, and R.J. Colonno Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro Antimicrob. Agents Chemother. 46 8 2002 2525 2532
71. S.R. Lewin, R.M. Ribeiro, T. Walters, G.K. Lau, S. Bowden, S. Locarnini, and A.S. Perelson Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed Hepatology 34 5 2001 1012 1020
72. M. Lu, B. Lohrengel, G. Hilken, T. Kemper, and M. Roggendorf Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes J. Virol. 76 1 2002 58 67
73. P.L. Marion, L.S. Oshiro, D.C. Regnery, G.H. Scullard, and W.S. Robinson A virus in Beechey ground squirrels that is related to hepatitis B virus of humans Proc. Natl. Acad. Sci. U.S.A. 77 1980 2941 2945
74. W.S. Mason, J. Cullen, G. Moraleda, J. Saputelli, C.E. Aldrich, D.S. Miller, B. Tennant, L. Frick, D. Averett, L.D. Condreay, and A.R. Jilbert Lamivudine therapy of WHV-infected woodchucks Virology 245 1998 18 32
75. W.S. Mason, G. Seal, and J. Summers Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus J. Virol. 36 1980 829 836
76. M.T. McManus, and P.A. Sharp Gene silencing in mammals by small interfering RNAs Nat. Rev. Genet. 3 10 2002 737 747
77. S. Menne, C.A. Roneker, B.E. Korba, J.L. Gerin, B.C. Tennant, and P.J. Cote Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection J. Virol. 76 11 2002 5305 5314
78. R.H. Miller, and W.S. Robinson Hepatitis B virus DNA in nuclear and cytoplasmic fractions of infected human liver Virology 137 1984 390 399
79. G. Moraleda, J. Saputelli, C.E. Aldrich, D. Averett, L. Condreay, and W.S. Mason Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus J. Virol. 71 1997 9392 9399
80. T. Moroy, A. Marchio, J. Etiemble, C. Trepo, P. Tiollais, and M. Buendia Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks Nature 324 1986 276 279
81. D. Mutimer, D. Pillay, P. Cook, D. Ratcliffe, K. O'Donnell, D. Dowling, J. Shaw, E. Elias, and P.A. Cane Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy J. Infect. Dis. 181 2 2000 713 716
82. S. Nafa, S. Ahmed, D. Tavan, C. Pichoud, F. Berby, L. Stuyver, M. Johnson, P. Merle, H. Abidi, C. Trepo, and F. Zoulim Early detection of viral resistance by determination of Hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic Hepatitis B Hepatology 32 5 2000 1078 1088
83. M. Nowak, S. Bonhoeffer, A. Hill, R. Boehme, H. Thomas, and H. McDade Viral dynamics in hepatitis B virus infection Proc. Natl. Acad. Sci. U.S.A. 93 1996 4398 4402
84. W. Offensperger, S. Offensperger, E. Walter, K. Teubner, G. Igloi, H. Blum, and W. Gerok In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides EMBO J. 12 1993 1257 1262
85. J. Petersen, M. Dandri, S. Gupta, and C.E. Rogler Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma Proc. Natl. Acad. Sci. U.S.A. 95 1 1998 310 315
86. C. Pichoud, B. Seignères, Z. Wang, C. Trepo, and F. Zoulim Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance Hepatology 29 1999 230 237
87. A. Prassolov, H. Hohenberg, T. Kalinina, C. Schneider, L. Cova, O. Krone, K. Frolich, H. Will, and H. Sirma New hepatitis B virus of cranes that has an unexpected broad host range J. Virol. 77 3 2003 1964 1976
88. S. Ren, and M. Nassal Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors J. Virol. 75 3 2001 1104 1116
89. D.D. Richman The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B Hepatology 32 4 Pt. 1 2000 866 867
90. M. Robaczewska, S. Guerret, J.S. Remy, I. Chemin, W.B. Offensperger, M. Chevallier, J.P. Behr, A.J. Podhajska, H.E. Blum, C. Trepo, and L. Cova Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver Gene Ther. 8 11 2001 874 881
91. Robaczewska, M., Narayan, R., Seignères, B., Schorr, O., Thermet, A., Podhajska, A.J., Trépo, C., Zoulim, F., Nielsen, P.E., Cova, L., in press. Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). J. Hepatol.
92. I. Schroder, B. Holmgren, M. Oberg, and B. Lofgren Inhibition of human and duck hepatitis B virus by 2′,3′-dideoxy-3′-fluoroguanosine in vitro Antivir. Res. 37 1 1998 57 66
93. U. Schultz, and F.V. Chisari Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes J. Virol. 73 4 1999 3162 3168
94. U. Schultz, J. Summers, P. Staeheli, and F.V. Chisari Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes [in process citation] J. Virol. 73 7 1999 5459 5465
95. C. Seeger, D. Ganem, and H.E. Varmus Biochemical and genetic evidence for the hepatitis B virus replication strategy Science 232 1986 477 484
96. C. Seeger, and J. Maragos Identification and characterization of the woodchuck hepatitis virus origin of DNA replication J. Virol. 64 1990 16 23
97. C. Seeger, and W.S. Mason Hepatitis B virus biology Microbiol. Mol. Biol. Rev. 64 1 2000 51 68
98. M. Seifer, R.K. Hamatake, R.J. Colonno, and D.N. Standring In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir Antimicrob. Agents Chemother. 42 1998 3200 3208
99. B. Seigneres, S. Aguesse-Germon, C. Pichoud, I. Vuillermoz, C. Jamard, C. Trepo, and F. Zoulim Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo J. Hepatol. 34 1 2001 114 122
100. B. Seigneres, P. Martin, B. Werle, O. Schorr, C. Jamard, L. Rimsky, C. Trepo, and F. Zoulim Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model Antimicrob. Agents Chemother. 47 6 2003 1842 1852
101. B. Seigneres, C. Pichoud, S.S. Ahmed, O. Hantz, C. Trepo, and F. Zoulim Evolution of Hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic Hepatitis B J. Infect. Dis. 181 4 2000 1221 1233
102. B. Seigneres, C. Pichoud, P. Martin, P. Furman, C. Trepo, and F. Zoulim Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses Hepatology 36 3 2002 710 722
103. M.A. Sells, M. Chen, and G. Acs Production of hepatitis B virus particles in hepG2 cells transfected with cloned hepatitis B virus DNA Proc. Natl. Acad. Sci. U.S.A. 84 1987 1005 1009
104. A. Severini, X.-Y. Liu, J. Wilson, and D. Tyrell Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-b-L-2′,3′-dideoxy- 3′-thyacytidine Antimicrob. Agents Chemother. 39 1995 1430 1435
105. A. Shlomai, and Y. Shaul Inhibition of hepatitis B virus expression and replication by RNA interference Hepatology 37 4 2003 764 770
106. R. Sprengel, E.F. Kaleta, and H. Will Isolation and characterization of a hepatitis B virus endemic in herons J. Virol. 62 1988 3832 3839
107. D.N. Standring, E.G. Bridges, L. Placidi, A. Faraj, A.G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J.L. Imbach, B. Hernandez, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, E. Cretton-Scott, R.F. Schinazi, M. Myers, M.L. Bryant, and J.P. Sommadossi Antiviral beta-L-nucleosides specific for hepatitis B virus infection Antivir. Chem. Chemother. 12 Suppl. 1 2001 119 129
108. J. Summers, A.R. Jilbert, W. Yang, C.E. Aldrich, J. Saputelli, S. Litwin, E. Toll, and W.S. Mason Hepatocyte turnover during resolution of a transient hepadnaviral infection Proc. Natl. Acad. Sci. U.S.A. 100 20 2003 11652 11659
109. J. Summers, J.M. Smolec, and R. Snyder A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks Proc. Natl. Acad. Sci. U.S.A. 75 1978 4533 4537
110. C. Sureau, J. Romet-Lemonne, J.I. Mullins, and M. Essex Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA Cell 47 1987 37 47
111. P. Testut, C.A. Renard, O. Terradillos, L. Vitvitski-Trepo, F. Tekaia, C. Degott, J. Blake, B. Boyer, and M.A. Buendia A new hepadnavirus endemic in arctic ground squirrels in Alaska J. Virol. 70 7 1996 4210 4219
112. R. Thimme, S. Wieland, C. Steiger, J. Ghrayeb, K.A. Reimann, R.H. Purcell, and F.V. Chisari CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection J. Virol. 77 1 2003 68 76
113. M. Tsiang, J.F. Rooney, J.J. Toole, and C.S. Gibbs Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy Hepatology 29 6 1999 1863 1869
114. P. Turelli, B. Mangeat, S. Jost, S. Vianin, and D. Trono Inhibition of hepatitis B virus replication by APOBEC3G Science 303 5665 2004 1829
115. J. Tuttleman, C. Pourcel, and J. Summers Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells Cell 47 1986 451 460
116. S. Urban, K.P. Fischer, and D.L. Tyrrell Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism Proc. Natl. Acad. Sci. U.S.A. 98 9 2001 4984 4989
117. S. Urban, and P. Gripon Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein J. Virol. 76 4 2002 1986 1990
118. J.P. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong, C.L. Brosgart, C.S. Gibbs, P. Parvaz, B. Werle, C. Trepo, and F. Zoulim Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient J. Hepatol. 39 6 2003 1085 1089
119. F. von Weizsacker, J. Kock, S. Wieland, W.B. Offensperger, and H.E. Blum Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis Hepatology 30 1 1999 308 315
120. G. von Weizsäcker, S. Wieland, J. Köck, W.-B. Offensperger, S. Offensperger, D. Moradpour, and H.E. Blum Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants Hepatology 26 1997 251 255
121. E. Walter, R. Keist, B. Niederöst, I. Pult, and H. Blum Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo Hepatology 24 1996 1 5
122. G. Wang, F. Zoulim, E. Leber, J. Kitson, and C. Seeger The role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses J. Virol. 68 1994 8437 8442
123. G.H. Wang, and C. Seeger The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis Cell 71 1992 633 670
124. G.J. Webster, S. Reignat, D. Brown, G.S. Ogg, L. Jones, S.L. Seneviratne, R. Williams, G. Dusheiko, and A. Bertoletti Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy J. Virol. 78 11 2004 5707 5719
125. B. Werle, K. Cinquin, P. Marcellin, S. Pol, M. Maynard, C. Trepo, and F. Zoulim Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy J. Viral Hepat. 11 1 2004 74 83
126. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, G. Lau, C. Trepo, P. Marcellin, Z. Goodman, W.E.t. Delaney, S. Xiong, C.L. Brosgart, S.S. Chen, C.S. Gibbs, and F. Zoulim Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 7 2004 1750 1758
127. C. Westland, W.t. Delaney, H. Yang, S.S. Chen, P. Marcellin, S. Hadziyannis, R. Gish, J. Fry, C. Brosgart, C. Gibbs, M. Miller, and S. Xiong Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 Gastroenterology 125 1 2003 107 116
128. L.M. Wolters, B.E. Hansen, H.G. Niesters, D. DeHertogh, and R.A. de Man Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B J. Hepatol. 37 1 2002 137 144
129. D.K. Wong, A.M. Cheung, K. O'Rourke, C.D. Naylor, A.S. Detsky, and J. Heathcote Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis [see comments] Ann. Intern. Med. 119 4 1993 312 323
130. X. Xiong, C. Flores, H. Yang, J.J. Toole, and C.S. Gibbs Mutations in hepatitis B DNA polymerase asssociated with resistance to lamivudine do not confer resistance to adefovir in vitro Hepatology 28 1998 1669 1673
131. T. Yamamoto, S. Litwin, T. Zhou, Y. Zhu, L. Condreay, P. Furman, and W.S. Mason Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil J. Virol. 76 3 2002 1213 1223
132. H. Yang, C. Westland, S. Xiong, and Delaney In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector W. E. t. 61 1 2004 27 36
133. W. Yang, and J. Summers Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination J. Virol. 69 1995 4029 4036
134. O. Yokosuka, M. Omata, F. Imazeki, K. Okuda, and J. Summers Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA Hepatology 5 5 1985 728 734
135. M. Yu, and J. Summers Multiple functions of capsid protein phosphorylation in duck hepatitis B virus replication J. Virol. 68 1994 4341 4348
136. X. Zhang, F. Zoulim, F. Habersetzer, S. Xiong, and C. Trépo Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B J. Med. Virol. 48 1996 8 16
137. T. Zhou, J.T. Guo, F.A. Nunes, K.L. Molnar-Kimber, J.M. Wilson, C.E. Aldrich, J. Saputelli, S. Litwin, L.D. Condreay, C. Seeger, and W.S. Mason Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections J. Virol. 74 24 2000 11754 11763
138. T. Zhou, J. Saputelli, C.E. Aldrich, M. Deslauriers, L.D. Condreay, and W.S. Mason Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine [in process citation] Antimicrob. Agents Chemother. 43 8 1999 1947 1954
139. F. Zoulim Detection of hepatitis B virus resistance to antivirals J. Clin. Virol. 21 3 2001 243 253
140. F. Zoulim A preliminary benefit-risk assessment of Lamivudine for the treatment of chronic hepatitis B virus infection Drug Saf. 25 7 2002 497 510
141. F. Zoulim Treatment of pre- and post-liver transplantation HBV infection: should we aim at combination therapy 38 6 2003 1353 1355
142. F. Zoulim, E. Dannaoui, C. Borel, O. Hantz, T.-S. Lin, S.-H. Liu, C. Trépo, and Y.-C. Cheng 2′,3′-Dideoxy-b-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo Antimicrob. Agents Chemother. 40 1996 448 453
143. F. Zoulim, and C. Seeger Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase J. Virol. 68 1994 6 13